Table 1

Frequency of FH-autoantibodies and CFHR1 deficiency in patients compared to healthy controls.

Total number of patients and controls

FH-autoantibody positive individuals

FH-autoantibody negative individuals

Odds Ratio for anti-FH positivity in CFHR1 deficiency

%

No.

CFHR1 deficiency

No. (%)

No.

CFHR1 deficiency

No. (%)

OR

95% CI

P-value


LA+

Sweden

64

9.4

6

5 (83.3)

58

1 (1.7)

285

15.4 to 5,280

<0.0001

Controls

Sweden

64

6.3

4

1 (25.0)

60

1 (1.7)

20

1.0 to 397

1.12

SLE

Low SLEDAI, Sweden

30

0.0

0

0 (0.0)

30

1 (3.3)

n.a1

Controls

Sweden

30

0.0

0

0 (0.0)

30

0 (0.0)

n.a.

SLE

High SLEDAI, Sweden

30

13.3

4

0 (0.0)

26

1 (3.8)

2.0

0.066 to 54.1

1

Controls

Sweden

30

10.0

3

0 (0.0)

27

1 (3.7)

6.3

0.17 to 231

1

RA

Sweden

97

16.5

16

2 (12.5)

81

5 (6.2)

2.0

0.38 to12.3

0.3

Controls

Sweden

97

2.1

2

0(0.0)

95

1(1.1)

12.3

0.44 to 384

1

RA

The Netherlands

217

9.2

20

0 (0.0)

197

7 (3.6)

n.a.

Controls

The Netherlands

161

3.1

5

0 (0.0)

156

13 (8.3)

n.a.

aHUS

Germany

103

11.7

12

3 (25.0)

91

4 (4.4)

6.45

1.25 to 33.05

0.04

Controls

Germany

20

5.0

1

0 (0.0)

19

0 (0.0)

n.a.


1n.a., not applicable due to 0% frequency

Foltyn Zadura et al. Arthritis Research & Therapy 2012 14:R185   doi:10.1186/ar4016

Open Data